Favorable outcome in T-cell acute lymphoblastic leukemia with mediastinal mass during pregnancy. 1988

E Sigler, and D Varon, and G Lugassy, and Y Skurnik, and R Borenstein, and A Berrebi
Kaplan Hospital, Rehovot, Israel.

UI MeSH Term Description Entries
D007945 Leukemia, Lymphoid Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts. Leukemia, Lymphocytic,Lymphocytic Leukemia,Lymphoid Leukemia,Leukemias, Lymphocytic,Leukemias, Lymphoid,Lymphocytic Leukemias,Lymphoid Leukemias
D008479 Mediastinal Neoplasms Tumors or cancer of the MEDIASTINUM. Cancer of Mediastinum,Mediastinal Cancer,Cancer of the Mediastinum,Mediastinum Cancer,Mediastinum Neoplasms,Neoplasms, Mediastinal,Cancer, Mediastinal,Cancer, Mediastinum,Cancers, Mediastinal,Cancers, Mediastinum,Mediastinal Cancers,Mediastinal Neoplasm,Mediastinum Cancers,Mediastinum Neoplasm,Neoplasm, Mediastinal,Neoplasm, Mediastinum,Neoplasms, Mediastinum
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011252 Pregnancy Complications, Neoplastic The co-occurrence of pregnancy and NEOPLASMS. The neoplastic disease may precede or follow FERTILIZATION. Complications, Neoplastic Pregnancy,Neoplastic Pregnancy Complications,Pregnancy, Neoplastic Complications,Complication, Neoplastic Pregnancy,Neoplastic Pregnancy Complication,Pregnancies, Neoplastic Complications,Pregnancy Complication, Neoplastic
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy
D013601 T-Lymphocytes Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen. T Cell,T Lymphocyte,T-Cells,Thymus-Dependent Lymphocytes,Cell, T,Cells, T,Lymphocyte, T,Lymphocyte, Thymus-Dependent,Lymphocytes, T,Lymphocytes, Thymus-Dependent,T Cells,T Lymphocytes,T-Cell,T-Lymphocyte,Thymus Dependent Lymphocytes,Thymus-Dependent Lymphocyte

Related Publications

E Sigler, and D Varon, and G Lugassy, and Y Skurnik, and R Borenstein, and A Berrebi
May 2021, Postgraduate medical journal,
E Sigler, and D Varon, and G Lugassy, and Y Skurnik, and R Borenstein, and A Berrebi
January 1984, Medical and pediatric oncology,
E Sigler, and D Varon, and G Lugassy, and Y Skurnik, and R Borenstein, and A Berrebi
December 2002, Medical and pediatric oncology,
E Sigler, and D Varon, and G Lugassy, and Y Skurnik, and R Borenstein, and A Berrebi
January 1998, Medical and pediatric oncology,
E Sigler, and D Varon, and G Lugassy, and Y Skurnik, and R Borenstein, and A Berrebi
July 2010, International journal of hematology,
E Sigler, and D Varon, and G Lugassy, and Y Skurnik, and R Borenstein, and A Berrebi
June 1975, Pediatrics,
E Sigler, and D Varon, and G Lugassy, and Y Skurnik, and R Borenstein, and A Berrebi
January 2008, Pediatric hematology and oncology,
E Sigler, and D Varon, and G Lugassy, and Y Skurnik, and R Borenstein, and A Berrebi
March 2022, Journal of pediatric hematology/oncology,
E Sigler, and D Varon, and G Lugassy, and Y Skurnik, and R Borenstein, and A Berrebi
March 1981, Archives of pathology & laboratory medicine,
E Sigler, and D Varon, and G Lugassy, and Y Skurnik, and R Borenstein, and A Berrebi
December 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,
Copied contents to your clipboard!